High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes (PRIME)
High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes; PRIME: P: Precision R: Radiosurgery I: Intervention M: Minimal Invasive Surgical Approach E: EYESIGHT
High-precision radiosurgery followed by minimally invasive surgical approach in patients with high-prominence uveal melanomas: modern radiation techniques and outcomes. Evaluation of outcome regarding multiparametric parameters and co-factors
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Description détaillée
The aim here is to prospectively evaluate modern technical standards. The aim of this study is to assess the influence of the updated basic diagnostics and high-resolution diagnostics for radiation planning and the new technical therapy standards (therapy options in application: volume modulated rapid arc technique (VMAT) / online arc technique (VMAT) / online onboard image-guidance (IGRT), by means of the newly established Clinic for Radiation Therapy 2019-2021) depending on known prognostic parameters for quality assurance of the long-term outcome (overall survival, local tumor control). This will lay the basis for standardizing treatment parameters as far as possible, but also to introduce improvements in the treatment of future patients.
Scientific background (state of research (with literature references) and
Derivation of the research question (rationale)):
The eye can be affected by several neoplastic processes, which can lead either primarily or secondary to systemic metastasis. The most common primary tumors of the eye include conjunctival melanoma and uveal melanoma. Metastases from systemic malignant diseases, particularly of the breast and lungs, can also affect the eye.
A combination of ophthalmologic examination, MRI and additional tests and cytologic/histopathologic evaluation leads to an accurate diagnosis.
Depending on the tumor manifestation, treatment consists of a multimodal concept. In the case of uveal melanomas and the aim of preserving the globe and and visual acuity preservation, radiotherapy is one of the most important treatment modalities that can be applied.
In the last 20 years, radiotherapy has developed rapidly away from two-dimensional modulated, three-dimensional techniques. But here too the high level of technical diversity in radiotherapy and ever newer technical innovations, there is a broad spectrum of radiotherapy. Standard therapy can be performed using modern devices, the high-precision stereotactic linear accelerators (irradiation devices), can be safely further optimized. This is to be tested in the Department of Radiotherapy.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Maja Guberina, PD MD
- Numéro de téléphone: 0201 723 83121
- E-mail: maja.guberina@uk-essen.de
Lieux d'étude
-
-
-
Essen, Allemagne
- Recrutement
- University Hospital Essen
-
Contact:
- Maja Guberina
- Numéro de téléphone: +4920127232321
- E-mail: maja.guberina@uk-essen.de
-
Essen, Allemagne, 45147
- Recrutement
- Maja Guberina
-
Contact:
- Maja W Strahlentherapie
- Numéro de téléphone: +492017232321
- E-mail: maja.guberina@uk-essen.de
-
-
Germany / NRW
-
Essen, Germany / NRW, Allemagne, 45147
- Recrutement
- Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West
-
Contact:
- Maja Guberina, PD Dr. med. (MD), specialist
- Numéro de téléphone: +492017232321
- E-mail: maja.guberina@uk-essen.de
-
Contact:
- Ina Grübel
-
Chercheur principal:
- Maja Guberina, PD Dr. med. (MD)
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Inclusion Criteria:
- Resectability, high-prominent and high risk uveal melanoma
Exclusion Criteria:
- EOE
- lux defect (If a medical report notes a "lux defect" alongside this, it refers to a deficit in light perception (from the Latin lux for light). It means the eye's ability to sense light, darkness, or light direction is impaired)
La description
Inclusion Criteria:
- Functional Resectability,
- Technical Resectability
- high-prominent uveal melanoma
Exclusion Criteria:
- EOE
- At least in part remaining eye function that can be saved
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Local control
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Local control |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Visual acuity:
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Visual function assessed separately for each eye. Visual acuity: decimal scale,range 2,0 - 0,01: decimal acuity scale |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Quality of Life, ophthalmic cancer-specific quality of life
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Quality of Life, ophthalmic cancer-specific quality of life 1) EORTC QLQ-OPT30 (ophthalmic cancer-specific quality of life): Scores range from 0-100; higher scores indicate greater visual impairment, ocular symptoms, and functional difficulties. |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Progression Free Survival
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Progression Free Survival |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Overall Survival
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Overall Survival |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Visual acuity:
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Visual function assessed separately for each eye. Visual acuity: decimal scale,range 2,0 - 0,01: decimal acuity scale; furthermore, 1.Count-fingers, 2.hand-motion and 3.light-perception categories are recorded separately when acuity cannot be quantified: for each item: value yes / no |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Visual field
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Visual field: Automated perimetry, Visual Field Index (VFI, %): 0 % - 100%, |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Quality of Life general quality of life
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
EORTC QLQ-C30 (general quality of life): Scores range from 0-100; A) higher scores indicate better functioning/global quality of life B) symptom scores: indicate greater symptom burden on symptom scales. |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Retinal Nerve Fiber Layer
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Optical coherence tomography (OCT): Peripapillary retinal nerve fiber layer (RNFL) thickness, measured in µm and classified in percentiles (regarding normal values) |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Cornea
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
corneal outcome: thickness measured in µm |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Cornea
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Corneal outcome modified Stocker's classification: category 0 No damage no injury category 1 corneal guttae without epithelial or stromal edema. category 2 corneal guttae with epithelial or stromal edema. category 3 corneal edema associated with scar formation. category 4 corneal opacification with neovascularization, modified Stocker's classification |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Corneal overall outcome classification
Délai: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
category 0 No corneal-ulcus category 1 Irregular punctate epithelial defects category 2 Non-healing epithelial defects / persistent epithelial defect (PED) category 3 Ulcer perforation |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 21-10377-BO
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
dependent on the project
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .